secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090311
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q2 revenue $87.2M (+87% YoY); Auvelity sales $65.0M (+135%)
------------------------------------------------------------------

- Total net product revenue $87.2M, up 87% YoY; Auvelity $65.0M (+135%), Sunosi $22.1M (+16%).
- Net loss $79.3M ($1.67 per share) vs $67.2M ($1.54) in Q2 2023; cash $315.7M.
- NDA for AXS-07 in migraine resubmitted; NDA submission for AXS-14 in fibromyalgia expected Q3 2024.
- Patent litigation with Unichem settled; generic Sunosi entry allowed no earlier than June 30, 2042.
- Anticipated topline results: AXS-05 (AD agitation), solriamfetol (ADHD), AXS-12 (narcolepsy) in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/0000950170-24-090311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/axsm-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer